Who are Purinostat Mesylate for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chidamide+ Fulvestrant, Low dose valproate, Vorinostat (VOR), placebo to vorinostat, Romidepsin + CHOP, SHR2554 analog tablets; Chidamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/purinostat-mesylate-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Purinostat Mesylate for Injection — Competitive Intelligence Brief

Purinostat Mesylate for Injection (Purinostat Mesylate for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase inhibitor. Area: Oncology.

phase 3 Histone deacetylase inhibitor Histone deacetylases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Purinostat Mesylate for Injection (Purinostat Mesylate for Injection) — Chengdu Zenitar Biomedical Technology Co., Ltd. Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Purinostat Mesylate for Injection TARGET	Purinostat Mesylate for Injection	Chengdu Zenitar Biomedical Technology Co., Ltd	phase 3	Histone deacetylase inhibitor	Histone deacetylases
Chidamide+ Fulvestrant	Chidamide+ Fulvestrant	Liaoning Cancer Hospital & Institute	marketed	HDAC inhibitor + selective estrogen receptor degrader (combination therapy)	Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα)
Low dose valproate	Low dose valproate	Mario Negri Institute for Pharmacological Research	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDACs)
Vorinostat (VOR)	Vorinostat (VOR)	University of North Carolina, Chapel Hill	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)
placebo to vorinostat	placebo to vorinostat	Merck Sharp & Dohme LLC	phase 3	Histone deacetylase inhibitor	Histone deacetylases
Romidepsin + CHOP	Romidepsin + CHOP	The Lymphoma Academic Research Organisation	phase 3	HDAC inhibitor + chemotherapy combination	Histone deacetylases (HDAC)
SHR2554 analog tablets; Chidamide	SHR2554 analog tablets; Chidamide	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Histone deacetylase inhibitor	Histone deacetylases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase inhibitor class)

Celgene · 1 drug in this class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
Evopoint Biosciences Inc. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
NCIC Clinical Trials Group · 1 drug in this class
PharmaMar · 1 drug in this class
Telik · 1 drug in this class
Tianjin Medical University Cancer Institute and Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Purinostat Mesylate for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/purinostat-mesylate-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab